Zbigniew Nowecki

Eerstelijns Camizestrant for Emerging ESR1-Mutated Gevorderd Breast Cancer.

The New England journal of medicine · 7 augustus 2025

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonstero...

Clinical cancer research : an official journal of the American Association for Cancer Research · 1 mei 2025

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positi...

The Lancet. Oncology · 2024-11

Inavolisib plus fulvestrant plus palbociclib bij PIK3CA-gemuteerd mammacarcinoom: INAVO120 fase III

The New England journal of medicine · 31 oktober 2024

Capivasertib plus fulvestrant bij HR-positief mammacarcinoom: CAPItello-291 geactualiseerde analyse

The Lancet. Oncology · 2024-09

Giredestrant bij ER-positief mammacarcinoom: fase III persevERA-AI

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juni 2024

Ribociclib plus endocriene therapie bij vroeg mammacarcinoom: NATALEE fase III

The New England journal of medicine · 21 maart 2024

T-DM1 plus pertuzumab versus taxaan-trastuzumab-pertuzumab na anthracycline bij HER2-positief mammacarcinoom: KAITLIN fase III

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 februari 2022

Adjuvant palbociclib bij vroeg mammacarcinoom: PALLAS definitief

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 januari 2022

Adjuvant olaparib bij BRCA1/2-gemuteerd mammacarcinoom: OlympiA fase III

The New England journal of medicine · 24 juni 2021

Palbociclib plus adjuvante endocriene therapie bij vroeg mammacarcinoom: PALLAS fase III interim

The Lancet. Oncology · 2021-02

Subcutaan pertuzumab-trastuzumab plus chemotherapie: FeDeriCa fase III

The Lancet. Oncology · 2021-01

Pembrolizumab plus chemotherapie versus placebo plus chemotherapie bij vroeg TNBC: KEYNOTE-522 event-vrije overleving

Lancet (London, England) · 5 december 2020

SB3 trastuzumab-biosimilar: fase III werkzaamheid, veiligheid en immunogeniciteit

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 april 2018